Cellectis develops gene-edited cell therapies focused on immuno-oncology and hematologic malignancies. The company's primary platform centers on allogeneic chimeric antigen receptor T-cell (CAR-T) products, which use TALEN gene-editing technology to create off-the-shelf cell therapies. Its clinical-stage pipeline includes ALLO-501 for large B-cell lymphoma, ALLO-819 for acute myeloid leukemia, and ALLO-213 targeting small cell lung cancer. The company also develops universal CAR-T (UCART) candidates, including UCART22 for relapsed or refractory B-cell acute lymphoblastic leukemia and UCART123 for acute myeloid leukemia, alongside cema-cel for chronic lymphocytic leukemia.
The company operates as a clinical-stage biotechnology firm without approved products or meaningful revenue streams. Cellectis maintains operations primarily in Paris, France, where it was incorporated in 1999, with 216 full-time employees as of the last reported period. The company is listed on Nasdaq and maintains a market capitalization of approximately $0.4 billion.
No 10-K filings found.